Premium
Crosslinking in infectious keratitis‐experimental and clinical data
Author(s) -
Szentmary N.
Publication year - 2017
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2017.04135
Subject(s) - keratitis , acanthamoeba , microbiology and biotechnology , staphylococcus epidermidis , staphylococcus aureus , pseudomonas aeruginosa , penicillin , acanthamoeba keratitis , medicine , antibiotics , biology , bacteria , ophthalmology , genetics
Summary The effect of crosslinking ( CXL ) on human corneal cells, microorganisms and on viral, bacterial, mycotic and acanthamoeba keratitis is summarized. Keratocyte and human endothelial cell viability decreases significantly at 0.1% riboflavin concentration (P < 0.01) while the percentage of CD 34 (P < 0.01) and alpha‐ SMA positive keratocytes (P < 0.05) increases. CXL may be effective against Staphylococcus aureus, Staphylococcus epidermidis and pseudomonas aeruginosa in vitro, even if they are metichillin, oxacillin or penicillin resistant. In clinical practice, CXL may be used as an alternative treatment option in bacterial, mycotic and acanthamoeba keratitis, if they are therapy resistant.